Competing in These 3 Markets Could Send Eli Lilly Stock Soaring
Unlike many of its big pharma peers, Eli Lilly (NYSE: LLY) is a growth stock that's likely to maintain a faster-than-average pace of expansion over the next few years. Between its massive portfolio of already-approved medicines and its efforts to compete in three large and quickly growing markets, it has an incredibly attractive combination of limited risk and long-term upside.
Let's take a look at what those three markets are, and what the company is doing that should drive its success -- hopefully bringing shareholders along on its ascent.
Until launched a pair of drugs to treat Alzheimer's in the last couple of years, no medicines were thought to slow the disease's progression. Now, the market is open for business, and Eli Lilly is likely to be the next player to make a major push to compete. GlobalData, a research business, thinks the market for Alzheimer's therapies could be as large as $13 billion by 2030.
Source Fool.com
Biogen Inc. Stock
The stock is one of the favorites of our community with 51 Buy predictions and 1 Sell predictions.
With a target price of 291 € there is a positive potential of 49.0% for Biogen Inc. compared to the current price of 195.3 €.
